Created in 2013, SYNSIGHT is a game changer in drug discovery by developing the first platform combining cell-based microscopy that train AI models, to generate new chemical entities. The benefits are to increase the productivity of your R&D and secure your drug discovery programs.
Its innovative platform and technologies can be directly applied to RNA-protein and protein-protein interactions. Its cellular assay is unique and is able to qualify and quantify directly in human cells these challenging interactions. The MTBench characterizes the efficacy of small molecule modulators in cell (Hit identification and IC50 measurement). This cellular assay, easy to setup as medium or high-throughput screening level combined to biophysical assays, are then able to train our multiparametric AI models to select and generate new chemical entities.